Two Ways of Managing Blood Pressure During Clot-Dissolving Treatment for Stroke
Compares two blood pressure approaches in adults receiving clot-dissolving treatment for ischemic stroke.
Plain-language title generated from the registry record
Registry title: Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07279259, who can take part
Where in China
- Shanghai East HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai East Hospital
- Trial code
- NCT07279259
- Record updated
- 21 January 2026
- Original description
This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).Read full original descriptionShow less
Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management, EAST-BP
This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).
Inclusion: Age 18 to 80 years (inclusive); Patients with acute ischemic stroke; Planned to receive intravenous thrombolysis within 4.5 hours of onset; Elevated blood pressure: Before receiving intravenous thrombolysis treatment, blood pressure is elevated: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg (defined as two consecutive measurements within 2 minutes); Informed consent signed (or signed by a proxy).
Exclusion: Intracranial or spinal surgery within the last 3 months; major surgery within the last 2 weeks; arterial puncture at a site not easily compressed for hemostasis within the last 7 days; Currently participating in other drug or device clinical trials; Intracranial hemorrhage is indicated on CT or MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma); History of intracranial hemorrhage; severe head trauma or stroke within the last 3 months; Gastrointestinal or urinary system bleeding within the last 3 weeks; Active visceral hemorrhage, known bleeding diathesis or significant bleeding disorders within the past 6 months; Severe ischemic stroke (NIHSS score > 25); Epileptic seizures at the time of stroke onset; Various terminal diseases with an expected survival of ≤ 3 months; Any other physical conditions where the doctor deems participation in this study may be detrimental to the patient; mRS score > 2 before onset of the disease; Acute bleeding tendency, including platelet count < 100×10\^9/L or other bleeding tendencies; Received low-molecular-weight heparin orally within 24 hours; taking warfarin with INR > 1.7 or PT > 15 seconds; used a new oral anticoagulant within 48 hours; Blood glucose < 2.8 mmol/L or > 22.2 mmol/L; Intracranial tumors, giant intracranial aneurysms; Aortic dissection; Large area cerebral infarction indicated on head CT or MRI (infarction area > 1/3 of the middle cerebral artery territory); Pregnant or lactating women.